Voyager Therapeutics

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$24,629
$29,578
$19,516
$90,061
Gross Profit
24,629
-4,874
18,320
88,726
EBITDA
-12,648
-13,633
-14,987
55,398
EBIT
-13,780
-15,025
-16,183
54,063
Net Income
-9,044
-10,141
-11,330
56,395
Net Change In Cash
24,629
29,578
19,516
90,061
Free Cash Flow
-28,226
-32,547
56,626
-26,617
Cash
112,525
76,127
143,078
68,802
Basic Shares
57,851
57,721
57,117
45,078

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$250,008
$40,907
$37,415
$171,128
Gross Profit
157,836
40,907
37,415
62,375
EBITDA
126,455
-44,646
-68,453
31,201
EBIT
122,014
-50,837
-73,618
27,384
Net Income
132,330
-46,408
-66,032
36,741
Net Change In Cash
250,008
40,907
37,415
171,128
Cost of Revenue
-18,738
12,993
19,442
Free Cash Flow
74,663
-15,000
-55,134
-108,813
Cash
68,802
98,959
117,433
104,440
Basic Shares
44,569
38,356
37,668
37,348

Earnings Calls

Quarter EPS
2024-09-30
-$0.16
2024-06-30
-$0.18
2024-03-31
-$0.20
2023-12-31
$1.25